Navigation Links
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Date:1/7/2008

lemia can be present in two forms: homozygous (hoFH), where the same defective gene is inherited from both parents, or heterozygous (heFH), where the defective gene is inherited from only one parent so that some function is preserved. The homozygous form is a very rare condition estimated to affect approximately one in a million people. Children with hoFH are at high risk for early coronary events and sudden death as young as age one. HeFH is more common, with a prevalence of approximately one in 500, and patients with heFH also experience elevated LDL-cholesterol and are at high risk for early coronary events. For undiagnosed or untreated heFH, the cumulative risk of a coronary heart disease (CHD) by age 60 years is 60-85% among men and 30-50% among women, with a mean age of onset of approximately 47 years.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease and other areas of
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
3. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
4. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
5. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
6. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
7. Genzyme Launches Cholestagel(R) in Europe
8. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
9. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
10. Genzyme Recognized by Scientists as a Top Employer
11. Genzyme Receives Approval to Market Elaprase(R) in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... $8.1 Million Financing in Connection With Acquisition ... Reverse Stock Split Planned for January 2008, LONDON, ... that the Company has:, - Signed an agreement to acquire ... Israel. The acquisition,is expected to close tomorrow. The initial consideration is ...
... Calif., Dec. 4 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... community on its latest developments in several of its,therapeutic ... and Analyst Briefing that will be held from 4:30 ... The presentation will be webcast live and may be ...
... - Associated Forum Provides Resources for Healthcare Professionals, ... ... 4 The Liko-sponsored Safe Lifting,Portal today announced the launch of ... associated safe lifting,forum, called "Safe Lifters," will allow healthcare professionals to,discuss ...
Cached Biology Technology:Amarin Signs Agreement to Acquire Ester Neurosciences 2Amarin Signs Agreement to Acquire Ester Neurosciences 3Amarin Signs Agreement to Acquire Ester Neurosciences 4Amarin Signs Agreement to Acquire Ester Neurosciences 5Amarin Signs Agreement to Acquire Ester Neurosciences 6Amarin Signs Agreement to Acquire Ester Neurosciences 7Amarin Signs Agreement to Acquire Ester Neurosciences 8Amarin Signs Agreement to Acquire Ester Neurosciences 9Amarin Signs Agreement to Acquire Ester Neurosciences 10Amarin Signs Agreement to Acquire Ester Neurosciences 11Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2New Online 'Help Desk' Offers Safe Lifting Assistance to Healthcare Facilities 2
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... A Kansas State University engineer has developed ... remotely detects improvised explosive devices. The same technique ... Dunn, the Steven M. and Kay L. Theede ... and nuclear engineering, and his research team have ... underground or in car trunks. The distance detection ...
(Date:4/17/2014)... If a restaurant ... he can expect his premises to be trashed. Warnings like ... is enough to make restaurant owners pay up. Similarly, mafia-like ... in other birds, nests. If the host birds throw the ... destroying the entire nest. Consequently, it is beneficial for hosts ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... held secrets of the earth,s history locked in its icy ... on the environments that have been sealed beneath miles of ... from nine institutions including LSU have been funded ... Science Foundation, or NSF, to get to the bottom of ...
... the deadly superbug MRSAan infection-causing bacteria resistant to most common ... is making its way into hospitals, according to a study ... The new threat is easily picked up in ... the overall burden of MRSA within hospitals, the report found. ...
... that a common oral bacterium may exacerbate autoimmune disease. ... a Common Human Bacterium Represent a New Class of TLR2 ... issue of The American Journal of Pathology . ... the brain and spinal cord, affects nearly 1 in 700 ...
Cached Biology News:LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2
HSV 1 IgM...
Epstein-Barr Virus (EBV) (EBNA-1)...
X box-binding protein 1...
... Rabbit polyclonal to Neuron navigator 1 ( Abpromise ... Antigen: Synthetic peptide conjugated to KLH derived ... Mouse Neuron navigator 1. (Note: the amino ... available as ab32208 .) ...
Biology Products: